Inactive Instrument

Press Releases Fresenius SE & Co KGaA OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

06-20	New version of clinic atlas available	DP
06-19	Hospital atlas to be slimmed down	DP

Fresenius : Investor Relations Company Presentation	06-18	PU
Fresenius : Capital Markets Day 2024	06-05	PU
Fresenius : outlines growth strategy for its Care Provision Platform – improved Fresenius Helios’ FY/24 outlook and raised ambitions	06-05	PU
Fresenius : Appoints Internationally Experienced Biopharma Expert to the Fresenius Kabi Management Board	05-29	PU
Fresenius : Announces FDA Acceptance for Review of Denosumab Biosimilar Application	05-27	PU
Fresenius : Resolutions of the Annual General Meeting of Fresenius SE & Co. KGaA	05-17	PU
Fresenius : Annual General Meeting 2024, Fresenius	05-16	PU
Fresenius : Quarterly Financial Report Q1 2024 (IFRS)	05-08	PU
Fresenius : Conference Call Q1/2024	05-08	PU
Fresenius : exits its Investment Company Vamed	05-08	PU
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024	05-07	EQ
Fresenius : divests Vamed’s rehabilitation business	05-02	PU
Fresenius : successfully completes divestment of hospital stake in Peru	04-23	PU
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne, its Third Approved Biosimilar in the U.S.	04-16	AQ
Fresenius : Investor Relations Company Presentation	04-12	PU
Fresenius : Chairman Letter	04-07	PU
Fresenius : MAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment	04-04	PU
Fresenius : Management Board buys own shares	04-04	PU
DD: Fresenius SE & Co. KGaA: Robert Möller, buy	04-04	EQ
DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy	04-04	EQ

No results for this search

FRESENIUS : Preparing for a strong(er) future performance

May 10, 2024 at 03:46 am